Published in Gene Therapy Weekly, August 24th, 2006
"HGF is a promising agent for the treatment of intractable liver disease, due to its mitogenic, anti-apoptotic, and anti-fibrotic effects. We investigated the effect of recombinant human HGF (rh-HGF) on the development of both hepatocellular carcinoma (HCC) and preneoplastic nodules in rats fed a CDAA diet, an animal model of hepatocarcinogenesis resembling human development of HCC with cirrhosis," wrote C. Nakanishi and colleagues, Kyoto University Hospital.
"From weeks 13 to 48 of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.